Harvoni is approved in Japan for the treatment of hepatitis C genotype 1. The cure rates were 100%. This study is evaluating the incidence of side effects in a ‘real world’ setting.
Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection
To read the entire clinical trial description, click here…Share This Page